Investor AB splits Mölnlycke in two: 38% margin on one side, 11% on the other

Mölnlycke appears to be one medical-technology company. In reality, it combines a highly profitable wound-care champion with a much lower-margin surgical-products business. Investor AB intends to separate them in 2027. For shareholders, the point is not legal restructuring: it is the chance to see where value is actually created inside Investor's largest private holding.

What does Mölnlycke actually make?

Mölnlycke supplies hospitals and healthcare professionals. One part develops advanced dressings, wound-treatment products and antiseptics. The other provides surgical drapes, procedure trays, protective clothing and operating-room gloves.

The businesses share customers and a medical setting, but not the same economics. Wound care relies more heavily on differentiated products, intellectual property and recurring clinical relationships. Surgical consumables operate in more competitive markets exposed to manufacturing costs, tenders and purchasing pressure from hospitals.

Investor AB, through Patricia Industries, therefore plans to create two separate companies in 2027:

Both companies will remain owned by Patricia Industries. The announcement is therefore neither a sale nor an announced initial public offering.

62% of sales produce roughly 85% of EBITDA

Applying the published margins to rounded sales gives a useful order of magnitude: about EUR494 million of EBITDA for wound care and EUR88 million for surgical activities.

The wound-care company would therefore account for close to 62% of combined sales, but about 85% of combined EBITDA. These are Opulion calculations based on rounded data, not a substitute for future separate accounts.

This gap shows why one consolidated account can mislead. Growth in surgical products may increase group revenue without creating as much value as one euro of growth in wound care.

What Mölnlycke represents for Investor shareholders

At 30 June, Investor valued Mölnlycke at SEK75.26 billion. It represented 36.2% of Patricia Industries excluding cash and 6.2% of Investor AB's adjusted net asset value.

Adjusted net asset value is the estimated value of Investor's holdings after net debt. Put simply, roughly six kronor out of every hundred of the holding company's net value depended on Mölnlycke.

The separation also connects with our article on Investor AB's near-unlevered balance sheet. Financial strength lets the holding company support two different paths: fund innovation and acquisitions in wound care while giving the surgical business the resources to improve margins and industrial efficiency.

Why separation can help without automatically creating value

A separation clarifies responsibility. Each management team can receive distinct growth, margin, investment and acquisition targets. Their performances will no longer be averaged into one number.

It also permits more precise capital allocation. Wound care may prioritise clinical research and differentiated products. Surgical activities may focus investment on automation, productivity and procurement.

Separation also creates costs: technology systems, administrative functions, contracts, taxation and organisation. Investor has not yet disclosed these costs or stand-alone financial objectives for the two future companies.

The next test will be operational

The split makes the portfolio easier to understand but does not yet prove that value will rise. Three numbers will matter: separation cost, organic growth in each company and the direction of the surgical margin.

If the 11% business gradually moves towards higher industrial standards without sacrificing customers, the separation will have created a useful framework. If central costs are duplicated and performance stalls, it will merely have moved accounting boundaries.

The immediate benefit for Investor shareholders is therefore transparency. Their largest private asset will no longer be presented as a homogeneous block when its two engines generate radically different returns.

This content is general financial information. It is not investment advice, a solicitation or a personalised recommendation.